Trial
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.
- Histologically confirmed invasive carcinoma of the breast
- Patient ≥ 18 years of age
- No prior radiation therapy to the chest, neck or axilla
- No prior history of ipsilateral breast cancer (invasive disease or DCIS)
- No history of prior or concurrent contralateral invasive breast cancer
- No significant post mastectomy complications requiring an unplanned re-operation or admission for IV antibiotics
- Radiation oncologist intends to treat all target volumes described in section 7.4 and respect all normal tissues identified in section 7.4.3 in accordance with the dosimetric constraints described
- Patient must have undergone immediate reconstruction at the time of mastectomy or be planning to undergo reconstruction within 8 months after radiation
- No other malignancy within 5 years of registration
Principal Investigator Name
Regan Look, MD
Oncology Clinical Research
Last Updated:
Monday, August 23, 2021 02:02:59 PM